Pharmaceutical giant Eli Lilly announced it will spend up to $7 billion to acquire private biotechnology company Kelonia Therapeutics, aiming to secure a new generation of CAR-T (a type of cancer immunotherapy) technology that does not require ex vivo modification of immune cells, positioning itself to take the lead in the &#34;in vivo gene therapy&#34; track.
According to statements from both parties, Eli Lilly will pay an upfront cash amount of $3.25 billion to Kelonia shareholders, with the remaining payments linked to technology development milestones.
Kelonia's core project currently targets multiple myeloma (market size was approximately $23.5 billion in 2023 and is expected to grow to $33.2 billion by 2030), focusing on patients who have no response to existing therapies or have relapsed. Human clinical trials have already been initiated.
Jacob Van Naarden, President of Eli Lilly's Oncology Business Unit, stated in the announcement that currently &#34;only a small fraction of eligible patients can receive&#34; CAR-T therapy, while Kelonia's technology &#34;has the potential to bring rapid and durable treatment responses in a simpler format, thereby changing this status quo.&#34;
Eli Lilly's stock price had fallen cumulatively by 14% year-to-date as of last Friday. Following the announcement, the stock price remained relatively stable, reflecting a generally neutral market attitude toward the deal.
<img src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/76c76b45-eff1-48c1-81de-ee147a92651d.png?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://wpimg-wscn.awtmt.com/76c76b45-eff1-48c1-81de-ee147a92651d.png"/>
<h2>&#34;In Vivo CAR-T&#34;: Simplifying Processes and Breaking Traditional Limitations</h2>
The treatment process for traditional CAR-T therapy is highly complex: immune cells must first be extracted from the patient, genetically modified ex vivo, and then reinfused into the patient after chemotherapy preconditioning. This process is not only time-consuming and costly to manufacture but also limits the large-scale promotion of the therapy.
Kelonia's &#34;in vivo&#34; CAR-T approach bypasses the aforementioned steps. This technology achieves gene modification of immune cells directly within the patient through a single infusion, requiring no ex vivo operations or chemotherapy preconditioning. This &#34;off-the-shelf&#34; characteristic theoretically significantly reduces treatment complexity and improves patient accessibility.
Earlier this February, Eli Lilly had already positioned itself in similar technology by acquiring Orna Therapeutics for up to $2.4 billion; the latter also focuses on &#34;in vivo&#34; CAR-T, targeting autoimmune diseases such as rheumatoid arthritis. This acquisition of Kelonia further strengthens Eli Lilly's strategic depth in this emerging therapy field.
<h2>First Indication Targets Multiple Myeloma</h2>
Kelonia's first indication targets multiple myeloma, a blood cancer occurring in white blood cells. According to data from the American Cancer Society, approximately 36,000 people are expected to be diagnosed with the disease in the U.S. this year, with nearly 11,000 deaths.
According to Bloomberg Industry Research data, the global multiple myeloma treatment market was valued at approximately $23.5 billion in 2023 and is projected to grow to $33.2 billion by 2030. The vast and continuously expanding market space makes this indication a core battleground for competing pharmaceutical companies.
Trung Huynh, an analyst at RBC Capital Markets, pointed out in a research report that the Kelonia transaction &#34;places Eli Lilly at the forefront of a potentially transformative technology that may have broad application prospects beyond multiple myeloma.&#34;

LLYZ

'In vivo CAR-T' technology eliminates the need to extract and modify immune cells, achieving gene modification via a single infusion. It has the potential to disrupt the complex processes of traditional cancer immunotherapies and improve patient accessibility. Kelonia's first indication for its 'in vivo CAR-T' technology targets multiple myeloma, a market valued at approximately $23.5 billion in 2023 and projected to reach $33.2 billion by 2030

- Eli Lilly has announced a deal to acquire private biotech company Kelonia Therapeutics for up to $7 billion, aiming to acquire a new generation CAR-T technology that simplifies the treatment process.  
- Kelonia's technology targets multiple myeloma patients who are unresponsive or relapsed and is currently undergoing human clinical trials, with the potential to significantly reduce treatment complexity and cost.  
- This acquisition is part of Eli Lilly’s strategy to enhance its position in the emerging field of in vivo gene therapy, following its earlier purchase of Orna Therapeutics aimed at similar technologies.

Wallstreetcn

Eli Lilly

Defiance Daily Target 2X Short LLY ETF

Health Care Select Sector SPDR

Invesco Biotechnology & Genome ETF

SPDR S&P Biotech

Ark Genomic Revolution ETF

Proshares Ultra Nasdaq Biotech

iShares Global Healthcare

Defiance Daily Target 2X Long LLY ETF

VanEck Biotech ETF

Invesco Nasdaq Biotechnology ETF

First Trust NYSE Arca Biotech Index Fd

Direxion S&P Biotech Bull 3X

ALPS Medical Breakthrough

iShares US Pharma

Direxion Daily LLY Bull 2X Shares

iShares Biotechnology ETF

VG Health

ROYAL BANK OF CANADA

Eli Lilly Announces $7 Billion Acquisition of Kelonia: Pioneering the 'In Vivo CAR-T' Frontier and Leading Gene Therapy Revolution